# A PHASE I DOSE ESCALATION STUDY OF TOPICAL BEXAROTENE IN WOMEN AT HIGH RISK FOR BREAST CANCER

> **NIH NIH N01** · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2020 · $106,072

## Abstract

The proposed clinical trial will evaluate safety and toxicity of topical bexarotene 1% gel to the breast in healthy women at high risk for breast cancer and bexarotene concentration in the breast tissue.

## Key facts

- **NIH application ID:** 10251826
- **Project number:** 261201200034I-P00005-26100012-1
- **Recipient organization:** UNIVERSITY OF TX MD ANDERSON CAN CTR
- **Principal Investigator:** POWEL BROWN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $106,072
- **Award type:** —
- **Project period:** 2017-09-01 → 2021-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10251826

## Citation

> US National Institutes of Health, RePORTER application 10251826, A PHASE I DOSE ESCALATION STUDY OF TOPICAL BEXAROTENE IN WOMEN AT HIGH RISK FOR BREAST CANCER (261201200034I-P00005-26100012-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10251826. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*